

# Aptamer-Bioconjugate Drug Delivery Device

NE\_2012\_16

Aareet Shermon · Nathan Jones · Abdel R. Elsayed · Ryan Wagner

Sponsor – EcoSynthetix Inc.

Consultant – Professor Juewen Liu

Nanotechnology Engineering, University of Waterloo

# Table of Contents

1. Cancer and Current Treatments
2. Advantages of Nanotechnology in Drug Delivery
3. Design
4. Fabrication
5. Results
6. Moving Forward
7. Conclusion
8. Acknowledgements

# Cancer

- 40% of Canadians will receive a diagnosis of cancer over their lifetime ([www.cancer.ca](http://www.cancer.ca))
  - Standard chemotherapy agents kill rapidly dividing cells
    - Cancer, hair follicles, gastrointestinal cells
    - Significant toxicity
- Limited therapeutic use, particularly in advanced stage disease

# Advantages of Nanomaterials in Drug Delivery

# 1. Size

- Long Biological Half-life<sup>1</sup>
- Enhanced Permeability and Retention Effect (EPR)<sup>1</sup>

# 2. Controlled Release

- Longer effectiveness of treatment<sup>1</sup>

# 3. Large Surface Area

- Targeting Ligands
- PEG, Contrast Agents

1. Wang AZ, Langer R and Farokhzad OC. "Nanoparticle delivery of cancer drugs". Annual Reviews of Medicine, 63 (2012) 185.


# Design Requirements

1. Biocompatible
2. Device uptake by cancer cells
3. Able to load drug
4. Controlled sustained release profile
5. Able to kill cancer cells with encapsulated drug
6. Can be produced reliably and give similar outcomes

# Our Design

# Aptamer – “to fit”


- AS-1411 ssDNA oligomer of 22 nucleic units – in phase II clinical trials
- Binds to nucleolin receptor which is expressed by many cancer cells
- Poor biological lifetime if non-conjugated





# EcoSphere®

- Product of EcoSynthetix
- Cross-linked starch nanogel
- Uniform small size (120 nm diameter)



**WATERLOO**  
**ENGINEERING**

# Doxorubicin & Docetaxel



- Commonly used chemotherapeutic agents

**ECOSYNTHETIX®**  
ADVANCED POLYMERS FROM PLANET EARTH®

# Why Starch?

- Many other materials have been studied for drug delivery: PLGA-PEG; Liposomes; porous silica; gold nanoparticles
- EcoSphere starch nanoparticles can be reliably produced at large scale for low cost
- Starch is a food material – biocompatible
- Hydrophilic – results in lengthy biological lifetime
- Multitude of reactions to modify starch

# Drug Delivery Device (Patent Pending)

EcoSphere

- Can vary cross-linking density
- Negatively charged

Drug

- Loaded actively or passively
- 5% by-mass loading

Aptamer

- Covalently bound
- Attached using EDC/NHS reaction

**WATERLOO**  
**ENGINEERING**


**ECOSYNTHETIX®**  
ADVANCED POLYMERS FROM PLANET EARTH®

# Fabrication Process



Based on [6] Mangalam et al.  
“Cellulose/DNA hybrid nanomaterials”

# Initial Nanoparticle


EcoSphere Starch Nanoparticle



# Tempo Oxidation




TEMPO







# Carbodiimide Cross-linking










**WATERLOO**  
**ENGINEERING**

**ECOSYNTHETIX**<sup>®</sup>  
ADVANCED POLYMERS FROM PLANET EARTH<sup>®</sup>

# Results

# Characterization of Device


	Unmodified EcoSphere	Carboxylated EcoSphere	Aptamer Bioconjugate
Size (nm)	$169 \pm 15.2$	$141.2 \pm 11.2$	$156.2 \pm 32.4$
Zeta Potential (mV)	$4 \pm 2.3$	$-25 \pm 0.8$	$-31 \pm 1.2$




- \* Size using NanoSight LM-20
- \* Zeta using Brookhaven Zetasizer

**WATERLOO**  
**ENGINEERING**

**ECOSYNTHETIX**<sup>®</sup>  
ADVANCED POLYMERS FROM PLANET EARTH<sup>®</sup>



**Fluorescence Microscope – HeLa cells, 48 hour incubation**  
**Blue is cell nucleus, red is fluorescent label on DNA/ device**



**Confocal Microscope Images – HeLa Cells, 2 hour incubation**


**Blue is cell nucleus/cytoplasm, green is cell cytoplasm, red is DNA/device**

**WATERLOO  
ENGINEERING**


**ECOSYNTHETIX®**  
ADVANCED POLYMERS FROM PLANET EARTH®



# Normalized Cellular Uptake (2 hr. exposure for HeLa cells)



# Drug Release Profile




- Doxorubicin release - Using Dialysis tubing of 25 kDa (Doxorubicin = 0.5 kDa)
- DOX measured using ELISA: excitation 470 nm, emission 550 nm

**WATERLOO**  
**ENGINEERING**

**ECOSYNTHETIX®**  
ADVANCED POLYMERS FROM PLANET EARTH®

# LDH Assay – HeLa Cells (24 hr. exposure)






# Future Work

- Move testing to *in vivo* (animal studies) for further validation of targeting
- Load different therapeutic agents into Ecosphere
- Conjugate to high Z material ( $\text{TiO}_2$ , Fe) for use as imaging aid/ radiation sensitizer

# Design Checklist:




1. New drug delivery platform using starch nanoparticles
2. Biocompatible and ideal size for “passive” targeting
3. Device uptake by cancer cells
4. Able to load drug and shows sustained release profile
5. Able to kill cancer cells with encapsulated drug better than free drug
6. Can be produced reliably to give similar outcomes





# Acknowledgements

- Prof. Juewen Liu and the students in his lab, Alex Ip, Neeshma Dave, and Jimmy Huang.
- Dr. Steven Bloembergen and Dr. Ian McLennan of EcoSynthetix Inc.
- PhD Candidate David Donkor – help with confocal images

# Sources of Information



- [1] Wang AZ, Langer R and Farokhzad OC. "Nanoparticle delivery of cancer drugs". Annual Reviews of Medicine, 63 (2012) 185.
- [2] M. Blank, T. Weinschenk, M. Priemer, and H. Schluesener, "Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen.," *The Journal of biological chemistry*, vol. 276, May. 2001, pp. 16464-8.
- [3] N. Dave, M.Y. Chan, P.-J.J. Huang, B.D. Smith, and J. Liu, "Regenerable DNA-functionalized hydrogels for ultrasensitive, instrument-free mercury(II) detection and removal in water.," *Journal of the American Chemical Society*, vol. 132, Sep. 2010, pp. 12668-73.
- [4] O.C. Farokhzad, S. Jon, A. Khademhosseini, T.-N.T. Tran, D. a Lavan, and R. Langer, "Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.," *Cancer research*, vol. 64, Nov. 2004, pp. 7668-72.
- [5] O.C. Farokhzad, J.M. Karp, and R. Langer, "Nanoparticle-aptamer bioconjugates for cancer targeting.," *Expert opinion on drug delivery*, vol. 3, May. 2006, pp. 311-24.
- [6] A.P. Mangalam, J. Simonsen, and A.S. Benight, "Cellulose/DNA hybrid nanomaterials.," *Biomacromolecules*, vol. 10, Mar. 2009, pp. 497-504.



# Questions?

**WATERLOO**  
**ENGINEERING**

  
**ECOSYNTHETIX®**  
ADVANCED POLYMERS FROM PLANET EARTH®

